John Gordon Freund
CIK 1296771 · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.36M
Companies
12
Total Filings
126
Lifetime Open-Market Net
$480.73B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SIBN | Director | 146,025 | $18.80 | $2.75M | -$49.95M | 21 | 2026-06-08 |
| COLL | Director | 107,081 | $25.98 | $2.78M | $1.05M | 14 | 2026-05-20 |
| STRO | Director | 0 | $25.04 | $0 | -$14.16M | 13 | 2024-06-10 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Director | 0 | — | — | -$9.95M | 15 | 2019-12-12 |
| PRTO | Director | 59,397 | $28.18 | $1.67M | $7.20M | 8 | 2019-11-12 |
| ESPR | Director | 33,325 | $3.18 | $106.0K | $0 | 7 | 2019-04-29 |
| XENOPORT INC (XNPT) Delisted | Director | 0 | — | — | $17.87M | 18 | 2016-07-06 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Director | 1,058,920 | $8.37 | $8.86M | $2.10M | 1 | 2014-02-21 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 208,097 | $0.86 | $179.0K | $4.84M | 1 | 2012-05-31 |
| MAPP | Director | 1,984 | $28.03 | $55.6K | $3.00M | 10 | 2011-05-23 |
| HANSEN MEDICAL INC (HNSN) Delisted | Director | 200,094 | — | — | $480.77B | 3 | 2009-06-17 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | Director | 304,761 | — | — | $0 | 1 | 2007-05-31 |
Recent Filings · Page 9 of 13
126 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-10-01 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −152,266 | -$3.07M | EDGAR |
| 2014-09-18 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −144,356 | -$2.48M | EDGAR |
| 2014-09-15 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −55,644 | -$946.5K | EDGAR |
| 2014-09-09 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −16,700 | -$250.7K | EDGAR |
| 2014-09-05 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Sell (S) | −183,300 | -$2.76M | EDGAR |
| 2014-03-14 | TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Other (J) | −295,507 | $0 | EDGAR |
| 2014-02-21 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Mixed | +1,176,548 | $2.10M | EDGAR |
| 2013-12-17 | — | Disp (D) | −2,287,951 | -$68.64M | |
| 2013-06-05 | — | Grant (A) | — | $0 | |
| 2013-05-16 | XENOPORT INC (XNPT) Delisted | Mixed | +5,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.